Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel

Alberto M. Marchevsky, Andras Khoor, Ann E. Walts, Andrew G. Nicholson, Yu Zhi Zhang, Victor Roggli, John Carney, Anja Roden, Henry D. Tazelaar, Brandon Larsen, Nolwenn LeStang, Lucian R. Chirieac, Sonja Klebe, Ming Sound Tsao, Marc De Perrot, Andrew Pierre, David M. Hwang, Yin P. Hung, Mari Mino-Kenudson, William TravisJennifer Sauter, Mary Beth Beasley, Françoise Galateau-Sallé

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Localized malignant mesotheliomas (LMM) is an uncommon and poorly recognized neoplasm. Its pathologic diagnosis is often surprising in patients with serosal/subserosal based localized tumors that are clinically suspicious for metastatic lesions or primary sarcomas. Once a tumor is diagnosed as “mesothelioma”, LMM is often mistaken for diffuse malignant mesothelioma (DMM). Best currently available evidence about LMM was collected from the literature and cases diagnosed by members of the International Mesothelioma Panel (IMP). One hundred and one (101) LMM have been reported in the English literature. Patients had localized tumors with identical histopathologic features to DMM. Patients ranged in age from 6 to 82 years; 75% were men. Most (82%) of the tumors were intrathoracic. Others presented as intrahepatic, mesenteric, gastric, pancreatic, umbilical, splenic, and abdominal wall lesions. Tumors varied in size from 0.6 to 15 cm. Most patients underwent surgical resection and/or chemotherapy or radiation therapy. Median survival in a subset of patients was 29 months. Seventy two additional LMM from IMP institutions ranged in age from 28 to 95 years; 58.3% were men. Sixty tumors (83.3%) were intrathoracic, others presented in intraabdominal sites. Tumors varied in size from 1.2 to 19 cm. Median survival for 51 cases was 134 months. Best evidence was used to formulate guidelines for the diagnosis of LMM. It is important to distinguish LMM from DMM as their treatment and prognosis is different. A multidisciplinary approach is needed for the diagnosis of LMM as it shows identical histopathology and immunophenotype to DMM.

Original languageEnglish (US)
JournalModern Pathology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Pleural Solitary Fibrous Tumor
Mesothelioma
Neoplasms
Malignant Mesothelioma
Literature
Umbilicus
Survival
Abdominal Wall
Sarcoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin : best current evidence from the literature and the International Mesothelioma Panel. / Marchevsky, Alberto M.; Khoor, Andras; Walts, Ann E.; Nicholson, Andrew G.; Zhang, Yu Zhi; Roggli, Victor; Carney, John; Roden, Anja; Tazelaar, Henry D.; Larsen, Brandon; LeStang, Nolwenn; Chirieac, Lucian R.; Klebe, Sonja; Tsao, Ming Sound; De Perrot, Marc; Pierre, Andrew; Hwang, David M.; Hung, Yin P.; Mino-Kenudson, Mari; Travis, William; Sauter, Jennifer; Beasley, Mary Beth; Galateau-Sallé, Françoise.

In: Modern Pathology, 01.01.2019.

Research output: Contribution to journalArticle

Marchevsky, AM, Khoor, A, Walts, AE, Nicholson, AG, Zhang, YZ, Roggli, V, Carney, J, Roden, A, Tazelaar, HD, Larsen, B, LeStang, N, Chirieac, LR, Klebe, S, Tsao, MS, De Perrot, M, Pierre, A, Hwang, DM, Hung, YP, Mino-Kenudson, M, Travis, W, Sauter, J, Beasley, MB & Galateau-Sallé, F 2019, 'Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel', Modern Pathology. https://doi.org/10.1038/s41379-019-0352-3
Marchevsky, Alberto M. ; Khoor, Andras ; Walts, Ann E. ; Nicholson, Andrew G. ; Zhang, Yu Zhi ; Roggli, Victor ; Carney, John ; Roden, Anja ; Tazelaar, Henry D. ; Larsen, Brandon ; LeStang, Nolwenn ; Chirieac, Lucian R. ; Klebe, Sonja ; Tsao, Ming Sound ; De Perrot, Marc ; Pierre, Andrew ; Hwang, David M. ; Hung, Yin P. ; Mino-Kenudson, Mari ; Travis, William ; Sauter, Jennifer ; Beasley, Mary Beth ; Galateau-Sallé, Françoise. / Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin : best current evidence from the literature and the International Mesothelioma Panel. In: Modern Pathology. 2019.
@article{4337166695674e8f883c1fab4f0f9f78,
title = "Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel",
abstract = "Localized malignant mesotheliomas (LMM) is an uncommon and poorly recognized neoplasm. Its pathologic diagnosis is often surprising in patients with serosal/subserosal based localized tumors that are clinically suspicious for metastatic lesions or primary sarcomas. Once a tumor is diagnosed as “mesothelioma”, LMM is often mistaken for diffuse malignant mesothelioma (DMM). Best currently available evidence about LMM was collected from the literature and cases diagnosed by members of the International Mesothelioma Panel (IMP). One hundred and one (101) LMM have been reported in the English literature. Patients had localized tumors with identical histopathologic features to DMM. Patients ranged in age from 6 to 82 years; 75{\%} were men. Most (82{\%}) of the tumors were intrathoracic. Others presented as intrahepatic, mesenteric, gastric, pancreatic, umbilical, splenic, and abdominal wall lesions. Tumors varied in size from 0.6 to 15 cm. Most patients underwent surgical resection and/or chemotherapy or radiation therapy. Median survival in a subset of patients was 29 months. Seventy two additional LMM from IMP institutions ranged in age from 28 to 95 years; 58.3{\%} were men. Sixty tumors (83.3{\%}) were intrathoracic, others presented in intraabdominal sites. Tumors varied in size from 1.2 to 19 cm. Median survival for 51 cases was 134 months. Best evidence was used to formulate guidelines for the diagnosis of LMM. It is important to distinguish LMM from DMM as their treatment and prognosis is different. A multidisciplinary approach is needed for the diagnosis of LMM as it shows identical histopathology and immunophenotype to DMM.",
author = "Marchevsky, {Alberto M.} and Andras Khoor and Walts, {Ann E.} and Nicholson, {Andrew G.} and Zhang, {Yu Zhi} and Victor Roggli and John Carney and Anja Roden and Tazelaar, {Henry D.} and Brandon Larsen and Nolwenn LeStang and Chirieac, {Lucian R.} and Sonja Klebe and Tsao, {Ming Sound} and {De Perrot}, Marc and Andrew Pierre and Hwang, {David M.} and Hung, {Yin P.} and Mari Mino-Kenudson and William Travis and Jennifer Sauter and Beasley, {Mary Beth} and Fran{\cc}oise Galateau-Sall{\'e}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41379-019-0352-3",
language = "English (US)",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin

T2 - best current evidence from the literature and the International Mesothelioma Panel

AU - Marchevsky, Alberto M.

AU - Khoor, Andras

AU - Walts, Ann E.

AU - Nicholson, Andrew G.

AU - Zhang, Yu Zhi

AU - Roggli, Victor

AU - Carney, John

AU - Roden, Anja

AU - Tazelaar, Henry D.

AU - Larsen, Brandon

AU - LeStang, Nolwenn

AU - Chirieac, Lucian R.

AU - Klebe, Sonja

AU - Tsao, Ming Sound

AU - De Perrot, Marc

AU - Pierre, Andrew

AU - Hwang, David M.

AU - Hung, Yin P.

AU - Mino-Kenudson, Mari

AU - Travis, William

AU - Sauter, Jennifer

AU - Beasley, Mary Beth

AU - Galateau-Sallé, Françoise

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Localized malignant mesotheliomas (LMM) is an uncommon and poorly recognized neoplasm. Its pathologic diagnosis is often surprising in patients with serosal/subserosal based localized tumors that are clinically suspicious for metastatic lesions or primary sarcomas. Once a tumor is diagnosed as “mesothelioma”, LMM is often mistaken for diffuse malignant mesothelioma (DMM). Best currently available evidence about LMM was collected from the literature and cases diagnosed by members of the International Mesothelioma Panel (IMP). One hundred and one (101) LMM have been reported in the English literature. Patients had localized tumors with identical histopathologic features to DMM. Patients ranged in age from 6 to 82 years; 75% were men. Most (82%) of the tumors were intrathoracic. Others presented as intrahepatic, mesenteric, gastric, pancreatic, umbilical, splenic, and abdominal wall lesions. Tumors varied in size from 0.6 to 15 cm. Most patients underwent surgical resection and/or chemotherapy or radiation therapy. Median survival in a subset of patients was 29 months. Seventy two additional LMM from IMP institutions ranged in age from 28 to 95 years; 58.3% were men. Sixty tumors (83.3%) were intrathoracic, others presented in intraabdominal sites. Tumors varied in size from 1.2 to 19 cm. Median survival for 51 cases was 134 months. Best evidence was used to formulate guidelines for the diagnosis of LMM. It is important to distinguish LMM from DMM as their treatment and prognosis is different. A multidisciplinary approach is needed for the diagnosis of LMM as it shows identical histopathology and immunophenotype to DMM.

AB - Localized malignant mesotheliomas (LMM) is an uncommon and poorly recognized neoplasm. Its pathologic diagnosis is often surprising in patients with serosal/subserosal based localized tumors that are clinically suspicious for metastatic lesions or primary sarcomas. Once a tumor is diagnosed as “mesothelioma”, LMM is often mistaken for diffuse malignant mesothelioma (DMM). Best currently available evidence about LMM was collected from the literature and cases diagnosed by members of the International Mesothelioma Panel (IMP). One hundred and one (101) LMM have been reported in the English literature. Patients had localized tumors with identical histopathologic features to DMM. Patients ranged in age from 6 to 82 years; 75% were men. Most (82%) of the tumors were intrathoracic. Others presented as intrahepatic, mesenteric, gastric, pancreatic, umbilical, splenic, and abdominal wall lesions. Tumors varied in size from 0.6 to 15 cm. Most patients underwent surgical resection and/or chemotherapy or radiation therapy. Median survival in a subset of patients was 29 months. Seventy two additional LMM from IMP institutions ranged in age from 28 to 95 years; 58.3% were men. Sixty tumors (83.3%) were intrathoracic, others presented in intraabdominal sites. Tumors varied in size from 1.2 to 19 cm. Median survival for 51 cases was 134 months. Best evidence was used to formulate guidelines for the diagnosis of LMM. It is important to distinguish LMM from DMM as their treatment and prognosis is different. A multidisciplinary approach is needed for the diagnosis of LMM as it shows identical histopathology and immunophenotype to DMM.

UR - http://www.scopus.com/inward/record.url?scp=85072204842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072204842&partnerID=8YFLogxK

U2 - 10.1038/s41379-019-0352-3

DO - 10.1038/s41379-019-0352-3

M3 - Article

C2 - 31485011

AN - SCOPUS:85072204842

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

ER -